Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Director | June 10, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date June 10, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.95 · Expires 2036-06-10 | Direct | 40,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 40,000 · Balance 40,000 F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 30, 2026 22:17 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001140361-26-027008 · form4.xml · derivative · entry 1 Carmichael Gordon · CIK 0001982077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:22 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001140361-25-021789 · form4.xml · derivative · entry 1 Carmichael Gordon · CIK 0001982077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 14, 2024 Filed Aug 17, 2024 01:05 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001140361-24-037712 · form4.xml · derivative · entry 1 Carmichael Gordon · CIK 0001982077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2034-08-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 14, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 1,866 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050614 · form4.xml · derivative · entry 1 Carmichael Gordon · CIK 0001982077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,866 Underlying: Common Stock · 1,866 shares Expires 2033-10-31 F1 · derivative.exercise_date: 1 These options vest as to one-third on each of the first, second and third anniversaries of October 31, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.